期刊文献+

非黄嘌呤类腺苷阻断剂对慢性心衰心室重构及肾素-血管紧张素-醛固酮系统的影响 被引量:3

The effect of non -xanthine adenosine receptor antagonist on ventricular remodeling and RAAS in chronic heart failure
原文传递
导出
摘要 目的:探讨非黄嘌呤类腺苷阻断剂 SLV320对慢性心衰(CHF)动物实验模型心室重构及肾素-血管紧张素-醛固酮系统(RAAS)的影响。方法将40只普通级成年雄性新西兰兔予以阿霉素静脉注射建立CHF 模型,再按照随机原则分为:高剂量组,予以静脉注射 SLV320剂量为10.0μg·kg -1·d -1;中剂量组,剂量为5.0μg·kg -1·d -1;低剂量组,剂量为2.5μg·kg -1·d -1;呋塞米组,予以灌服呋塞米2.0 mg·kg -1· d -1。每组均为10只,连续用药1周。检测并比较实验前后四组的血浆肾素(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)、B 型钠尿肽(BNP)水平;检测并比较实验前后四组左室收缩末内径(LVESD)、左室舒张末内径(LVEDD)、左心室后壁厚度(LVPW)、左心射血分数(LVEF)、左室缩短分数(LVFS)、E /A 等心室功能指标;准确称重左心室及右心室,计算并比较四组左心室重量指数(LVWI)和右心室重量指数(RVWI)。结果实验前四组血浆 PRA、AngⅡ、ALD、BNP 水平差异无统计学意义(P >0.05),实验后四组各指标水平顺序为:高剂量组<中剂量组<低剂量组<呋塞米组(均 P <0.05)。实验前四组各心室功能指标差异无统计学意义(P >0.05),实验后 LVEF 及 LVFS 指标顺序为:高剂量组>中剂量组>低剂量组>呋塞米组(均P <0.05),而LVESD、LVEDD、LVPW、E /A 指标顺序为:高剂量组<中剂量组<低剂量组<呋塞米组(均 P <0.05)。治疗后 LVWI 及 RVWI 顺序为:高剂量组<中剂量组<低剂量组<呋塞米组(均 P <0.05)。结论SLV320能改善 CHF 的心室重塑及 RASS 系统,且具有剂量依赖性。 Objective To analyze the effect of non -xanthine adenosine receptor antagonist (SLV320)on the ventricular remodeling and renin -angiotensin -aldosterone system (RAAS)in animal experimental models of chronic heart failure (CHF).Methods The 40 healthy male New Zealand rabbits were received adriamycin by intra-venous injection to establishing the experimental animal models and were randomly divided into 4 groups,which were high -dosage group (injected with SLV320,10.0μg·kg -1 ·d -1 ),medium -dosage group (injected with SLV320, 5.0μg·kg -1 ·d -1 ),low -dosage group (injected with SLV320,2.5μg·kg -1 ·d -1 )and furosemide group (fed with furosemide,2.0mg·kg -1 ·d -1 ).Each group had 10 rabbits and continuous treated for one week.The indexes of plasma renin activity (PRA),angiotensinⅡ (AngⅡ),aldosterone (ALD)and beta ntriuretic peptide (BNP)were detected at pre -and post -treatment,and compared among 4 groups.The indexes of left ventricular end -systolic dimension (LVESD),left ventricular end -diastolic dimension (LVEDD),left ventricular posterior wall (LVPW), left ventricle ejection fraction (LVEF),left ventricular fractional shortening (LVFS)and E /A at pre -and post -treatment were detected by echocardiography and compared among 4 groups.The wet weigh of the left and right ventri-cle were weigh accurately.And the indexes of left ventricle weight index (LVWI)and the body weight index (BWI) were calculated and compared among 4 groups.Results The plasma levels of PRA,AngⅡ,ALD and BNP were no different among 4 groups before study (all P 〉0.05).The sequence of 4 groups on the plasma levels of RAAS indexes was high -dosage group 〈medium -dosage group 〈low -dosage group 〈furosemide group (all P 〈0.05).The ven-tricular function indexes were no different among 4 groups before study (all P 〉0.05).The sequence of 4 groups on the levels of LVEF and LVFS was high -dosage group 〉medium -dosage group 〉low -dosage group 〉furosemide group,and the sequences of LVESD,LVEDD,LVPW and E /A were high -dosage group 〈medium -dosage group 〈low -dosage group 〈furosemide group (all P 〈0.05).The sequences of 4 groups on the LVWI and RVWI were high-dosage group 〈medium -dosage group 〈low -dosage group 〈furosemide group (all P 〈0.05 ).Conclusion SLV320 can regulate the ventricular remodeling and RAAS in animal model of CHF and this effect was dose dependent.
出处 《中国基层医药》 CAS 2015年第16期2457-2460,共4页 Chinese Journal of Primary Medicine and Pharmacy
关键词 非黄嘌呤类腺苷阻断剂 心力衰竭 心室重构 肾素-血管紧张素-醛固酮系统 Non -xanthine adenosine receptor antagonist Heart failure Ventricular remodeling Renin -an-giotensin -aldosterone system
  • 引文网络
  • 相关文献

参考文献11

  • 1钱俊峰,姜红,葛均波.我国慢性心力衰竭流行病学和治疗现状[J].中国临床医学,2009,16(5):700-703. 被引量:107
  • 2Kiesman WF1, Elzein E, Zablocki J. A1 adenosine receptor antag- onists, agonists,and allosteric enhancers[ J ]. Handb Exp Pharma- col ,2009, ( 193 ) :25-58.
  • 3Pang PS, Mehra M, Maggioni AP,et al. Rationale, design, and re- suits from RENO-DEFEND 1 :a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospi- talized with acute heart failure[J]. Am Heart J,2011,161 (6) : 1012-1023.
  • 4无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3698
  • 5Schenone S, Brullo C, Musumeci F, et al. A1 receptors ligands: past, present and future trends [ J ]. Curr Top Med Chem,2010,10 (9) :878-901.
  • 6Marti C, Cole R, Kalogeropoulos A, et al. Medical therapy for a- cute decompensated heart failure:what recent clinical trials have taught us about diuretics and vasodilators [ J ]. Curt Heart Fail Rep,2012,9( 1 ) :1-7.
  • 7Gottlieb SS, Ticho B, Deykin A, et al. Effects of BG9928, an a- denosine A? receptor antagonist,in patients with congestive heart failure [ J ]. J Clin Pharmaco1,2011,51 (6) :899-907.
  • 8Mitrovic V, Seferovic P, Dodic S, et al. Cardio-renal effects of the AI adenosine receptor antagonist SLV320 in patients with heart failure[ J]. Circ Heart Fail,2009,2(6) :523-531.
  • 9Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antago- nists, agonists, and allostcric enhancers [ J ]. Handb Exp Pharma- col ,2009, ( 193 ) :25-58.
  • 10Cleland JG, Chiswell K, Teerlink JR, et al. Predictors of postdis- charge outcomes from information acquired shortly after admission for acute heart failure:a report from the Placebo-Controlled Ran- domized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function ( PROTECT ) Study [ J 1. Circ Heart Fail ,2014,7( 1 ) :76-87.

二级参考文献70

共引文献3773

同被引文献26

引证文献3

二级引证文献42

相关主题

;
使用帮助 返回顶部